癌症患者抗凝治疗期间复发性静脉血栓栓塞的管理:一项前瞻性队列研究
这项国际前瞻性观察性队列研究纳入94例癌症相关静脉血栓栓塞抗凝治疗期间复发的患者,最终分析81例。复发时55%使用直接口服抗凝药(DOAC),41%使用治疗剂量低分子肝素(LMWH),4%使用维持剂量LMWH。3个月随访时第二复发率10%、临床相关出血12%、死亡20%。剂量升级组与维持治疗剂量组VTE发生率相似,但后者临床相关出血更频繁(6% vs 25%)。
要点
- 复发时55%患者使用DOAC,41%使用治疗剂量LMWH,4%使用维持剂量LMWH。
- DOAC治疗者中51%换用超治疗剂量LMWH,42%换用治疗剂量LMWH,7%接受其他治疗。
- LMWH治疗者中70%剂量升级,18%维持原剂量,12%接受其他治疗。
核心结论
- 尽管三分之二患者接受了剂量升级,第二复发VTE风险仍然很高。
- 无论治疗强度如何,出血均常见,凸显该患者群体的管理挑战。
研究设计与样本
- 国际、前瞻性、观察性队列研究,2020年6月至2024年11月入组94例,最终分析81例。
- 患者按当地实践治疗,研究方案鼓励依据现行临床指南采用剂量升级策略。
- 主要结局为第二复发VTE和临床相关出血。
主要发现
- 复发VTE时,55%患者使用DOAC,41%使用治疗剂量LMWH,4%使用维持剂量LMWH。
- DOAC治疗患者中,51%换用超治疗剂量LMWH,42%换用治疗剂量LMWH,7%接受其他治疗。
- LMWH治疗患者中,70%剂量升级,18%维持原剂量,12%接受其他治疗。
- 3个月随访时,10%发生第二复发,12%发生临床相关出血,20%死亡。
- 剂量升级组与维持治疗剂量组VTE发生率相似,临床相关出血在后者更频繁(6% vs 25%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent venous thromboembolism (VTE) is a common complication in patients with cancer-associated VTE. Limited data are available on treatment, particularly in patients receiving direct oral anticoagulants (DOACs). OBJECTIVES: We aimed to evaluate current management strategies and outcomes in patients with cancer and recurrent VTE during treatment with low-molecular-weight heparin (LMWH) or DOACs. METHODS: This was an international, prospective, observational cohort study. Patients were treated according to local practice, although the study protocol encouraged the use of a dose-escalation strategy in accordance with current clinical guidelines. Primary outcomes were second recurrent VTE and clinically relevant bleeding. RESULTS: Between June 2020 and November 2024, 94 patients were enrolled, of whom 81 were included in the final analysis. At the time of recurrent VTE, 55% of patients were treated with a DOAC, 41% with therapeutic-dose LMWH, and 4% with maintenance-dose LMWH. Of DOAC-treated patients, 51% switched to supratherapeutic-dose LMWH, 42% to therapeutic-dose LMWH, and 7% received other treatments. Of LMWH-treated patients, 70% received dose escalation, 18% maintained the same dose, and 12% received other treatments. At the 3-month follow-up, 10% had developed a second recurrence, 12% clinically relevant bleeding, and 20% died. VTE incidence was similar between patients receiving dose escalation and those maintained on therapeutic doses, while clinically relevant bleeding was more frequent in the latter (6% vs 25%). CONCLUSION: The risk of second recurrent VTE was substantial despite two-thirds of patients receiving dose escalation. Bleeding was common regardless of treatment intensity, underscoring the challenges in this patient population.
引用
- Lanting VR, Bosch FTM, Martens ESL, et al. Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study. J Thromb Haemost. 2025. PMID: 40915572. doi:10.1016/j.jtha.2025.08.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。